Cargando…

Intravenous Tigecycline Facilitates Cure of Severe Clostridium difficile Infection (CDI) After Failure of Standard Therapy: A Case Report and Literature Review of Tigecycline Use in CDI

Standard treatment for severe Clostridium difficile infection (CDI) is oral vancomycin with metronidazole. After failure of this standard regimen, treatment becomes challenging. A young woman treated for septic shock developed CDI. Standard treatment failed and she was ineligible for fecal transplan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Navalkele, Bhagyashri D., Lerner, Stephen A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943546/ https://www.ncbi.nlm.nih.gov/pubmed/27419166 http://dx.doi.org/10.1093/ofid/ofw094

Ejemplares similares

1653 Results of a Treatment Protocol Encouraging First-Line Use of Fidaxomicin for Select Patients with Clostridium difficile Infection (CDI)
por: Navalkele, Bhagyashri, et al.
Publicado: (2014)

New advances in the treatment of Clostridium difficile infection (CDI)
por: Hedge, Dennis D, et al.
Publicado: (2008)

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI
por: Sattar, Abdul, et al.
Publicado: (2015)

Use of Electronic Data to Identify Risk Factors Associated with Clostridium difficile Infection (CDI) and to Develop CDI Risk Scores
por: Aukes, Laurie, et al.
Publicado: (2017)

Does Adjunctive Tigecycline Improve Outcomes in Severe-Complicated, Nonoperative Clostridium difficile Infection?
por: LaSalvia, Mary T., et al.
Publicado: (2017)

Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI)
por: Golan, Yoav, et al.
Publicado: (2017)

2365. Volatile Metabolite-Based Detection of Clostridium difficile Infection (CDI)
por: Aloum, Obadah, et al.
Publicado: (2019)

Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection
por: Britt, Nicholas S., et al.
Publicado: (2014)

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
por: Louie, Thomas J., et al.
Publicado: (2012)

Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI
por: Finn, Elaine, et al.
Publicado: (2021)

Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study
por: Zilberberg, Marya D, et al.
Publicado: (2014)

Bezlotoxumab (BEZ) for Prevention of Clostridium difficile Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS)
por: Dorr, Mary Beth, et al.
Publicado: (2017)

The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases
por: Olsen, Margaret A., et al.
Publicado: (2016)

527 Age-Related Changes in the Incidence of Community-Associated Clostridium Difficile Infection (CDI)
por: Faden, Howard
Publicado: (2014)

485. On- and Post-Antibiotic Effects on the Risk of Hospital-Acquired Clostridium difficile Infection (CDI)
por: Stevens, Vanessa, et al.
Publicado: (2018)

684. Characteristics of Patients with Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences
por: Guh, Alice, et al.
Publicado: (2023)

Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin
por: Lao, Dominador, et al.
Publicado: (2012)

A point-prevalence study on community and inpatient Clostridioides difficile infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018
por: Viprey, Virginie F, et al.
Publicado: (2022)

973 Use of Concomitant Antibiotics During Treatment for Clostridium difficile Infection (CDI) in Pediatric Inpatients
por: Stevens, Vanessa, et al.
Publicado: (2014)

467. Investigation of a Clostridium difficile Infection (CDI) Outbreak in a Community Teaching Hospital
por: Parker, Laura, et al.
Publicado: (2018)

1635 A Retrospective Study Comparing Outcomes of Present on Admission Clostridium difficile Infection (CDI) vs Non-present on Admission CDI at a Tertiary-care Hospital in Detroit
por: Awali, Reda A., et al.
Publicado: (2014)

Calprotectin and Lactoferrin Faecal Levels in Patients with Clostridium difficile Infection (CDI): A Prospective Cohort Study
por: Swale, Andrew, et al.
Publicado: (2014)

Applying fecal microbiota transplantation (FMT) to treat recurrent Clostridium difficile infections (rCDI) in children
por: Fareed, Shaaz, et al.
Publicado: (2018)

Are Patients with Prior Clostridium difficile Infection (CDI) a Potential Source of Transmission during Hospital Admissions?
por: Gonzalez-Orta, Melany, et al.
Publicado: (2017)

Predictors of 30-day All-cause Mortality in Veterans with First Recurrence of Clostridium difficile Infection (CDI)
por: Morrill, Haley, et al.
Publicado: (2017)

1980. Efficacy of an Oral Vancomycin Loading Dose (LD) in the Treatment of Confirmed Clostridium Difficile Infection (CDI)
por: Tirmizi, Samad, et al.
Publicado: (2018)

1122. Evaluation of Fecal Microbiota Transplant (FMT) in Elderly Patients With recurrent Clostridium difficile Infection (CDI)
por: Hassoun, Ali, et al.
Publicado: (2018)

Clostridium difficile Infection–Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds
por: Talbot, George H., et al.
Publicado: (2019)

Clostridioides difficile infection (CDI) during the COVID-19 pandemic
por: Spigaglia, Patrizia
Publicado: (2022)

1211. Response to Fecal Microbiota Transplant (FMT) in Refractory Clostridioides difficile Infection (CDI) is Modest Compared to Recurrent CDI in Hospitalized Patients
por: Shin, Jae Hyun, et al.
Publicado: (2020)

Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)
por: Vehreschild, Maria J. G. T., et al.
Publicado: (2018)

Tigecycline Induced Hyperpigmentation of the Skin
por: Vandecasteele, S. J., et al.
Publicado: (2016)

394. Impact of Misdiagnosis of Clostridioides difficile Infection (CDI) by Standard-of-care Specimen Collection and Testing on Estimates of Hospitalized CDI Incidence Among Adults in Louisville, Kentucky, 2019-2020
por: Ramirez, Julio A, et al.
Publicado: (2022)

Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam
por: Garneau, Julian R, et al.
Publicado: (2014)

Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection
por: Hung, Yuan-Pin, et al.
Publicado: (2015)

P028: Examining the relationship between fluoroquinolone use and Clostridium difficile infections (CDI): a meta-analysis
por: Formanek, MB, et al.
Publicado: (2013)

Use of Concomitant Antibiotics During Treatment for Clostridium difficile Infection (CDI) in Pediatric Inpatients: An Observational Cohort Study
por: Stevens, Vanessa W., et al.
Publicado: (2016)

Declining Rates of Clostridium difficile infections (CDI) in Veterans Affairs (VA) Long-term Care Facilities (LTCF)
por: Evans, Martin, et al.
Publicado: (2017)

470. Concomitant Antibiotic Use and Death Among a National Cohort of Veterans With Clostridium difficile Infection (CDI)
por: Appaneal, Haley, et al.
Publicado: (2018)

Investigational Treatment Agents for Recurrent Clostridioides difficile Infection (rCDI)
por: Kullar, Ravina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jtb1uabdsfh8cecd8i5ijb0df2